Angelo Belotti

11PUBLICATIONS
43CO-AUTHORS
Gene and molecular therapyMedical mycologyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 27, 2026
Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus.

|Mar 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience.

Stefania Oliva, Marina Martello, Elona Saraci

|Mar 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Fortunato Morabito, Enrica Antonia Martino, Monica Galli

|Jun 07, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.

Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti

|Apr 01, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.

Anna Furlan, Michele Cea, Laura Pavan

|Sep 15, 2021
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.

C Cattaneo, V Cancelli, L Imberti

Pageof 2

Frequent Collaborators

5 joint publications

Chiara Cattaneo

3 joint publications

Alessandra Tucci

2 joint publications

Alessandra Romano

2 joint publications

Federico Monaco